Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity (AFF008AA)

Inclusion Criteria: * Prior participation in AFF008, AFF008E and AFF008A * Written informed consent signed and dated by the patient and, preferentially, the caregiver * In the investigator's opinion, does not have visual or auditory impairments that would reduce the patients' ability to complete study questionnaires or be unable to receive instructions for These * Female patients of childbearing potential are eligible if they use a medically accepted contraceptive method * All changes in conventional PD therapies must be available to the sponsor; in particular pharmacologic symptomatic PD medication allowing transformation to a Levodopa standard dose * A potential participant should be on stable doses of all medications he/she is taking because of consisting illnesses according to medical history (except PD therapies, these will be recorded separately) for at least 30 days prior to Visit 1 if considered relevant by the investigator Exclusion Criteria: * Women of childbearing potential without birth control or pregnant women * Participation in another clinical trial within 3 months before Visit 1 (except AFF008A) * History of questionable compliance to visit schedule; patients not expected to complete the clinical trial * Autoimmune disease or allergy to components of the vaccine * History of cancer (Exceptions: non-melanoma skin cancer, intraepithelial cervical neoplasia) * Active infectious disease (e.g., Hepatitis B, C) * Immunodeficiency * Significant systemic illness * Alcoholism or substance abuse * Prior and/or current treatment with experimental immunotherapeutics including IVIG with the exception of AFFITOPE® PD01A, with immune modulating drugs or treatment with deep brain stimulation * Venous status rendering it impossible to place an i.v. access